This company listing is no longer active
4541 Stock Overview
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nichi-Iko Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥35.00 |
| 52 Week High | JP¥804.00 |
| 52 Week Low | JP¥35.00 |
| Beta | -0.66 |
| 1 Month Change | -20.45% |
| 3 Month Change | -57.83% |
| 1 Year Change | -95.49% |
| 3 Year Change | -97.27% |
| 5 Year Change | -97.95% |
| Change since IPO | -98.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4541 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -2.8% | 2.8% | 3.6% |
| 1Y | -95.5% | 12.8% | 16.3% |
Return vs Industry: 4541 underperformed the JP Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: 4541 underperformed the JP Market which returned 1.6% over the past year.
Price Volatility
| 4541 volatility | |
|---|---|
| 4541 Average Weekly Movement | 17.0% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4541's share price has been volatile over the past 3 months.
Volatility Over Time: 4541's weekly volatility has decreased from 25% to 17% over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 2,656 | Shingo Iwamoto | www.nichiiko.co.jp |
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs.
Nichi-Iko Pharmaceutical Co., Ltd. Fundamentals Summary
| 4541 fundamental statistics | |
|---|---|
| Market cap | JP¥24.64b |
| Earnings (TTM) | -JP¥160.44b |
| Revenue (TTM) | JP¥182.88b |
0.1x
P/S Ratio-0.2x
P/E RatioIs 4541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4541 income statement (TTM) | |
|---|---|
| Revenue | JP¥182.88b |
| Cost of Revenue | JP¥195.69b |
| Gross Profit | -JP¥12.81b |
| Other Expenses | JP¥147.63b |
| Earnings | -JP¥160.44b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -227.92 |
| Gross Margin | -7.01% |
| Net Profit Margin | -87.73% |
| Debt/Equity Ratio | -389.9% |
How did 4541 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/31 02:09 |
| End of Day Share Price | 2023/03/28 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nichi-Iko Pharmaceutical Co., Ltd. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Hidemaru Yamaguchi | Citigroup Inc |
| Fumiyoshi Sakai | Credit Suisse |